LOSCOCCO, GIUSEPPE GAETANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.913
EU - Europa 1.231
AS - Asia 407
AF - Africa 10
SA - Sud America 4
Totale 3.565
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.905
RU - Federazione Russa 661
IT - Italia 203
SG - Singapore 149
IE - Irlanda 117
HK - Hong Kong 98
CN - Cina 93
SE - Svezia 81
CH - Svizzera 59
FI - Finlandia 50
JO - Giordania 27
IN - India 21
DE - Germania 20
TW - Taiwan 17
GB - Regno Unito 11
CI - Costa d'Avorio 9
CA - Canada 8
NL - Olanda 8
CZ - Repubblica Ceca 5
AT - Austria 4
ES - Italia 4
UA - Ucraina 4
AR - Argentina 2
BR - Brasile 2
FR - Francia 2
JP - Giappone 2
EG - Egitto 1
PL - Polonia 1
SI - Slovenia 1
Totale 3.565
Salva come PNG Salva come JPEG
Città #
Santa Clara 948
Dublin 117
Singapore 109
Fairfield 101
Chandler 96
Ashburn 85
Hong Kong 63
Bern 59
Moscow 55
Helsinki 44
Altamura 42
Woodbridge 42
Lawrence 41
Seattle 39
Cambridge 31
Florence 28
Houston 27
Wilmington 26
Princeton 25
Shanghai 23
Buffalo 22
New York 21
Boston 20
Mumbai 19
Beijing 16
Kent 15
Taipei 14
Ann Arbor 11
Fiesole 10
Abidjan 9
San Diego 9
Bremen 8
Falkenstein 8
Milan 7
Rome 7
Andover 6
Boardman 6
Los Angeles 6
Medford 6
Hangzhou 5
Prague 5
San Jose 5
Toronto 5
Washington 5
Yubileyny 5
Cagliari 4
Hillsboro 4
Lappeenranta 4
Napoli 4
Sesto Fiorentino 4
Vienna 4
West Jordan 4
Chengdu 3
Livorno 3
London 3
Reston 3
Barcelona 2
Brescia 2
Cipolletti 2
Cortona 2
Dearborn 2
Guangzhou 2
Hefei 2
Jacksonville 2
Kilburn 2
Le Vigan 2
Lugo 2
Maranello 2
Modena 2
Muggiò 2
New Taipei 2
Norwalk 2
Osteria del Gatto 2
Pisa 2
Prato 2
Pune 2
Recanati 2
Red Deer 2
Rimini 2
Romola 2
Sachigaoka 2
San Giovanni Valdarno 2
Sant'elpidio A Mare 2
Santa Croce sull'Arno 2
Seville 2
São Paulo 2
Abenberg 1
Arezzo 1
Baoding 1
Bari 1
Berlin 1
Brugherio 1
Cairo 1
Caronno Pertusella 1
Catania 1
Catanzaro 1
Clifton 1
Cologno Monzese 1
Ferrara 1
Fiumicino 1
Totale 2.365
Salva come PNG Salva come JPEG
Nome #
Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms 149
Kaposi Sarcoma in a patient treated with Ruxolitinib 137
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 131
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative 131
A case of disseminated Blastic Plasmocytoid Dendritic Cell Neoplasm 130
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 107
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 102
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 94
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases 93
Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera 91
JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis 90
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis 87
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease 84
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 83
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients 82
The HScore for secondary hemophagocytic lymphohistiocytosis, calculated without a marrow biopsy, is consistently low in patients with COVID-19 79
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma 77
Molecular Characterization of Response/Loss-of-Response to Ruxolitinib in Patients with Myelofibrosis 76
Impact of mutational profile on the management of myeloproliferative neoplasms: A short review of the emerging data 75
Quick complete response achievement with venetoclax and azacitidine in a case of relapsed disseminated blastic plasmacytoid dendritic cell neoplasm 74
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% 74
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis 73
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 72
Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms 72
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms 72
Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities 69
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera 65
Concomitant myeloproliferative neoplasm with eosinophilia, B and T cell lymphoblastic lymphoma/leukemia and mast cell proliferation driven by ZMYM2::FGFR1 rearrangement 65
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis 64
CALR mutation burden in essential thrombocythemia and disease outcome 63
Successful use of caplacizumab in a case of refractory acquired thrombotic thrombocytopenic purpura following subacute thyroiditis 62
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia 61
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis 59
Mutations and thrombosis in essential thrombocythemia 58
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis 56
T-Cell Lymphoblastic Lymphoma Arising in the Setting of Myeloid/Lymphoid Neoplasms with Eosinophilia: LMO2 Immunohistochemistry as a Potentially Useful Diagnostic Marker 56
Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis 53
SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates 48
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 43
Bone marrow involvement in small cell lung cancer 42
Myeloid sarcoma: more and less than a distinct entity 39
Skin Involvement by Hematological Neoplasms with Blastic Morphology: Lymphoblastic Lymphoma, Blastoid Variant of Mantle Cell Lymphoma and Differential Diagnoses 38
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 37
Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19 33
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives 32
Visceral Leishmaniasis 31
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia 30
One thousand patients with essential thrombocythemia: the Florence-CRIMM experience 30
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 25
Proposals for Revised International Working Group-European LeukemiaNet Criteria for Anemia Response in Myelofibrosis 20
Chronic myeloproliferative neoplasms with concomitant CALR mutation and BCR::ABL1 translocation: diagnostic and therapeutic implications of a rare hybrid disease 19
Neutrophil/lymphocyte ratio identifies low‐risk polycythaemia vera patients for early Ropeginterferon alfa‐2b therapy 18
Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms 18
Hepatoid thymic carcinoma in a polycythemia vera patient treated with ropeginterferon Alfa-2b: Clinical, histopathological and molecular correlates 16
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial 16
Aspirin therapy is associated with a lower risk of pregnancy loss in both JAK2‐ and CALR‐mutated essential thrombocythemia—A Mayo Clinic study of 200 pregnancies 15
Imatinib is effective in some PDGFRA/B‐negative hypereosinophilic syndromes: A step closer to unveiling underlying mechanisms 15
PCM1::JAK2 myeloproliferative neoplasm suggested by bone marrow histopathological features 15
null 1
When and how to transplant in myelofibrosis – recent trends 1
Totale 3.648
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.481
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.481
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020116 0 0 0 0 0 25 26 23 20 10 10 2
2020/202188 6 3 24 20 2 3 2 6 8 4 8 2
2021/2022143 1 0 1 2 3 3 0 40 15 3 30 45
2022/2023626 51 117 40 29 28 88 68 30 56 12 15 92
2023/2024501 28 35 58 24 56 68 22 93 9 47 36 25
2024/20252.068 85 236 156 403 805 383 0 0 0 0 0 0
Totale 3.648